Treatment of breast cancer with aromatase inhibitors – current status and future prospects
Open Access
- 1 July 1989
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 60 (1), 5-8
- https://doi.org/10.1038/bjc.1989.208
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast CancerDrugs, 1988
- Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer PatientsClinical Pharmacokinetics, 1987
- Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancerCancer Chemotherapy and Pharmacology, 1987
- Estrogen production and metabolism in normal postmenopausal women and postmenopausal women with breast or endometrial cancerEuropean Journal of Cancer and Clinical Oncology, 1986
- Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/dayEuropean Journal of Cancer and Clinical Oncology, 1985
- Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivoSteroids, 1981
- A Randomized Trial Comparing Surgical Adrenalectomy with Aminoglutethimide plus Hydrocortisone in Women with Advanced Breast CancerNew England Journal of Medicine, 1981
- Endogenous oestradiol-17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: Relationship to receptor contentEuropean Journal of Cancer (1965), 1980
- Estrone and estradiol content in human breast tumors: Relationship to estradiol receptorsThe Journal of Steroid Biochemistry and Molecular Biology, 1977
- Medical and surgical adrenalectomy in patients with advanced breast carcinomaCancer, 1977